RxDoctor Payments Data

Jack Berg, MD

Family Medicine · Shreveport, LANPI 1639160021

Payments from drug & device makers

$4,438in general payments, 2019–2025

Across 292 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$583
  • AstraZeneca$571
  • Merck$413
  • Pfizer$403
  • Novo Nordisk$383
  • Boehringer Ingelheim$343
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$4,427100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,438 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$52,253
Medicare patients
193
Services billed
811

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$54,228
TrulicityDulaglutide49$48,964
Tresiba Flextouch U-200Insulin Degludec33$41,431
JardianceEmpagliflozin24$37,201
JanuviaSitagliptin Phosphate22$28,572
OzempicSemaglutide29$27,297
Tresiba Flextouch U-100Insulin Degludec12$9,621
DilantinPhenytoin Sodium Extended11$2,482
Novolog FlexpenInsulin Aspart11$2,065
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,964
Memantine Hcl48$1,782
Albuterol Sulfate HfaAlbuterol Sulfate61$1,736
Rosuvastatin Calcium149$1,694
Atorvastatin Calcium194$1,690
Esomeprazole Magnesium52$1,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$403$56,70960 claims
Lilly USA, LLCTrulicity$583$48,96449 claims
Boehringer IngelheimJardiance$343$37,20124 claims
MerckJanuvia$413$28,57222 claims
Novo NordiskOzempic$383$27,29729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →